|
|
Article: ALLERGAN'S ALPHAGAN RECEIVES U.K. APPROVAL.
- Article from:
- Business Wire
- Article date:
- March 24, 1997
CopyrightCOPYRIGHT 1997 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif.--(BW HealthWire)--March 24, 1997--Allergan, Inc. (NYSE:AGN) today announced that it has received clearance from the Medicines Control Agency to market ALPHAGAN(r)(brimonidine) in the United Kingdom for the treatment of open-angle glaucoma and ocular hypertension. Allergan will seek approval to market ALPHAGAN(r) in the balance of the European community through the mutual recognition filing process.
ALPHAGAN(r) is a selective alpha2 agonist that significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor ...